BR0113078A - Uso de um composto, composto, processo para a preparação do mesmo, composição farmacêutica, e, método para produzir um efeito antiangiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente - Google Patents

Uso de um composto, composto, processo para a preparação do mesmo, composição farmacêutica, e, método para produzir um efeito antiangiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente

Info

Publication number
BR0113078A
BR0113078A BR0113078-1A BR0113078A BR0113078A BR 0113078 A BR0113078 A BR 0113078A BR 0113078 A BR0113078 A BR 0113078A BR 0113078 A BR0113078 A BR 0113078A
Authority
BR
Brazil
Prior art keywords
compound
formula
represents hydrogen
antiangiogenic
vascular permeability
Prior art date
Application number
BR0113078-1A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0113078A publication Critical patent/BR0113078A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Abstract

"USO DE UM COMPOSTO, COMPOSTO, PROCESSO PARA A PREPARAçãO DO MESMO, COMPOSIçãO FARMACêUTICA, E, MéTODO PARA PRODUZIR UM EFEITO ANTIANGIOGêNICO E/OU REDUTOR DA PERMEABILIDADE VASCULAR EM UM ANIMAL DE SANGUE QUENTE". A invenção diz respeito a compostos da fórmula (I): em que: o anel C é grupo heteroaromático bicíclico de 9 ou 10 membros contendo pelo menos um átomo de nitrogênio no anel ligado a Z e opcionalmente contendo um adicional de 1 a 3 heteroátomos, independentemente selecionados de O, S e N, com a condição de que o anel C não seja um grupo quinazolina, quinolina ou cinolina; nem qualquer um de G~ 1~, G~ 2~, G~ 3~, G~ 4~ e G~ 5~ é nitrogênio e os outros quatro são -CH- ou G~ 1~, G~ 2~, G~ 3~, G~ 4~ e G~ 5~ são todos -CH~; Z é -O-, NH-, -S-, CH~ 2~- ou um substituinte R^ 1^ direto pode estar ligado a qualquer átomo de carbono livre do grupo indol, azaindol ou indazol; m é um número inteiro de 0 a 2; R^ b^ representa hidrogênio ou outro valor como aqui definido; R^ 1^ representa hidrogênio, hidróxi, halogênio, alquila C~ 1-4~ ou qualquer outro valor como aqui definido; R^ 2^ representa hidrogênio, hidróxi, halogênio, ciano, nitro, trifluorometila, alquila C~ 1-3~, alcóxi C~ 1-3~, alquila C~ 1-3~ sulfanila, NR^ 3^R^ 4^ (em que R^ 3^ e R^ 4^, que podem ser os mesmos ou diferentes, cada um representa hidrogênio ou alquila C~ 1-3^) ou R^ 5^X^ 1^ -(em que R^ 5^ e X^ 1^ são como aqui definidos) e sais destes, a processos para a preparação de tais compostos, composições farmacêuticas contendo um composto da fórmula (I) ou um sal deste farmaceuticamente aceitável como ingrediente ativo e ao uso de um composto da fórmula (I) na fabricação de um medicamento para a produção de um efeito antiangiogênico e/ou redutor da permeabilidade vascular em animais de sangue quente. Os compostos da fórmula (I) e os seus sais farmaceuticamente aceitáveis inibem os efeitos do VEGF, uma propriedade de valor no tratamento de vários estados de doença incluindo o câncer e a artrite reumatóide.
BR0113078-1A 2000-08-09 2001-08-08 Uso de um composto, composto, processo para a preparação do mesmo, composição farmacêutica, e, método para produzir um efeito antiangiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente BR0113078A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00402257 2000-08-09
PCT/GB2001/003561 WO2002012227A2 (en) 2000-08-09 2001-08-08 Indole, azaindole and indazole derivatives having vegf inhibiting activity

Publications (1)

Publication Number Publication Date
BR0113078A true BR0113078A (pt) 2003-07-01

Family

ID=8173808

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0113078-1A BR0113078A (pt) 2000-08-09 2001-08-08 Uso de um composto, composto, processo para a preparação do mesmo, composição farmacêutica, e, método para produzir um efeito antiangiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente

Country Status (14)

Country Link
US (2) US20030207878A1 (pt)
EP (1) EP1311500A2 (pt)
JP (1) JP2004505965A (pt)
KR (1) KR20030029812A (pt)
CN (1) CN1245402C (pt)
AU (2) AU7993801A (pt)
BR (1) BR0113078A (pt)
CA (1) CA2416525A1 (pt)
IL (1) IL154034A0 (pt)
MX (1) MXPA03000874A (pt)
NO (1) NO20030628L (pt)
NZ (1) NZ523987A (pt)
WO (1) WO2002012227A2 (pt)
ZA (1) ZA200300489B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ306810B6 (cs) 1999-02-10 2017-07-19 Astrazeneca Ab Použití chinazolinového derivátu jako inhibitoru angiogeneze
UA72946C2 (uk) 1999-11-05 2005-05-16 Астразенека Аб Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf)
DE60112268T2 (de) 2000-03-06 2006-05-24 Astrazeneca Ab Verwendung von quinazolinderivate als inhibitoren der angiogenese
JP4970689B2 (ja) * 2000-04-07 2012-07-11 アストラゼネカ アクチボラグ キナゾリン化合物
US7268230B2 (en) 2002-02-01 2007-09-11 Astrazeneca Ab Quinazoline compounds
TW200400034A (en) 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
TWI272271B (en) * 2002-07-19 2007-02-01 Bristol Myers Squibb Co Process for preparing certain pyrrolotriazine compounds
JP4560483B2 (ja) * 2002-10-03 2010-10-13 ターゲジェン インコーポレーティッド 血管静態化物質およびそれらの使用法
PT1562955E (pt) 2002-11-04 2008-05-05 Astrazeneca Ab Derivados de quinazolina como inibidores da scr tirosina-cinase
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2004056807A1 (en) 2002-12-20 2004-07-08 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
CA2516078C (en) 2003-02-28 2014-04-29 Oxigene, Inc. Catechol compositions and use thereof
WO2004103159A2 (en) * 2003-05-14 2004-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for modulating endometrium
BRPI0510980A (pt) 2004-05-14 2007-11-27 Pfizer Prod Inc derivados de pirimidina para o tratamento do crescimento anormal de células
BRPI0511132A (pt) 2004-05-14 2007-11-27 Pfizer Prod Inc derivados de pirimidina e composição farmacêutica compreendendo os mesmos
WO2005111016A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
CL2007003158A1 (es) 2006-11-02 2008-05-16 Astrazeneca Ab Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion.
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
SG172393A1 (en) 2009-01-19 2011-07-28 Abbott Lab Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP2398324B1 (en) * 2009-02-23 2014-09-03 Merck Sharp & Dohme Corp. PYRAZOLO [4,3-c]CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
US8653079B2 (en) 2011-08-15 2014-02-18 Merck Sharp & Dohme Corp. Pyrazolo [4,3-C] cinnolin-3-one M1 receptor positive allosteric modulators
MX2016016928A (es) 2014-06-19 2017-04-25 Merial Inc Composiciones parasiticidas que comprenden derivados de indol, metodos y usos de los mismos.

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3987332A (en) * 1975-10-09 1976-10-19 Varian Associates Gang tuner for multi-cavity klystron
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5237629A (en) * 1992-03-19 1993-08-17 The United States Of America As Represented By The United States Department Of Energy Digitally controlled distributed phase shifter
US5440270A (en) * 1992-07-14 1995-08-08 Linear Technology Corporation Linear-phase filter having high gain selectivity
SE500986C2 (sv) * 1993-07-20 1994-10-17 Telia Ab Förfarande och anordning för synkronisering i digitalt transmissionssystem av typen OFDM
TW414798B (en) * 1994-09-07 2000-12-11 Thomae Gmbh Dr K Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation
US5639757A (en) * 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
US6395733B1 (en) * 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
GB9604361D0 (en) * 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
JP3727406B2 (ja) * 1996-03-07 2005-12-14 株式会社日立国際電気 関数変換演算器
HRP970371A2 (en) * 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
NZ334125A (en) * 1996-09-25 2000-10-27 Zeneca Ltd Quinoline derivatives inhibiting the effect of growth factors such as VEGF
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
CN1280580A (zh) * 1997-11-11 2001-01-17 辉瑞产品公司 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物
JPH11259454A (ja) * 1998-03-09 1999-09-24 Sharp Corp フーリエ変換装置
ATE459616T1 (de) * 1998-08-11 2010-03-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
US20030162795A1 (en) * 1998-10-22 2003-08-28 Pfizer Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
KR200212866Y1 (ko) * 1998-12-26 2001-02-15 서평원 선왜곡 방식 전력증폭기용 능동 왜곡신호 발생회로
US6982265B1 (en) * 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
NZ516292A (en) * 1999-05-21 2004-01-30 Bristol Myers Squibb Co Pyrrolotriazine inhibitors of kinases
GT200000158A (es) * 1999-09-28 2002-03-16 Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis.
ATE277933T1 (de) * 2000-06-06 2004-10-15 Pfizer Prod Inc Thiophenverbindungen zur verwendung als antikrebsmittel

Also Published As

Publication number Publication date
US20030207878A1 (en) 2003-11-06
CN1245402C (zh) 2006-03-15
ZA200300489B (en) 2004-04-19
EP1311500A2 (en) 2003-05-21
IL154034A0 (en) 2003-07-31
CN1468230A (zh) 2004-01-14
KR20030029812A (ko) 2003-04-16
JP2004505965A (ja) 2004-02-26
AU2001279938B2 (en) 2007-01-25
WO2002012227A2 (en) 2002-02-14
AU7993801A (en) 2002-02-18
MXPA03000874A (es) 2003-06-06
CA2416525A1 (en) 2002-02-14
US20060148819A1 (en) 2006-07-06
NO20030628D0 (no) 2003-02-07
NZ523987A (en) 2004-10-29
WO2002012227A3 (en) 2002-08-01
NO20030628L (no) 2003-04-08

Similar Documents

Publication Publication Date Title
BR0113078A (pt) Uso de um composto, composto, processo para a preparação do mesmo, composição farmacêutica, e, método para produzir um efeito antiangiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente
BRPI0008128B8 (pt) derivados de quinazolina, composições farmacêuticas contendo os mesmos, e, uso dos mesmos como inibidores de angiogênese
BRPI0015203B8 (pt) derivado de quinazolina, composição farmacêutica, e, uso de um composto
HUP0301069A2 (hu) Új biaril-karboxamidok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
EA200701991A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ИМИДАЗО [1,5-a]ПИРИДИНОВ, СПОСОБ ИХ ПОЛУЧЕНИЯ И СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
ATE294796T1 (de) Chinazolin derivate
BR9612043A (pt) Derivado de quinazolina,processos para preparar o mesmo e para produzir um efeito anti-angiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente necessitado de um tratamento desse tipo, e, composição farmacêutica
BR0113057A (pt) Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, método para produzir um efeito antiangiogênico e/ou efeito de redução da permeabilidade vascular em um animal de sangue quente em necessidade de tal tratamento
BR9707495A (pt) Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
MY141220A (en) Pyrazole derivatives as inhibitors of receptor tyrosine kinases
MXPA03000252A (es) Derivados de quinolina que tienen actividad de inhibicion de fcev.
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
DE3483798D1 (de) Dihydrodibenzocycloheptylidenethylamin-derivate.
KR940009185A (ko) 피라졸로[4,3-c]피리딘 및 세로토닌 재흡수 억제제로서의 이의 용도
RU95101437A (ru) Содержащее производные 3-фенилсульфонил-3,7-диазабицикло [3,3,1] нонана лекарственное средство, способ получения производных 3-фенилсульфонил-3,7-диазабицикло-[3,3,1]-нонана
YU160990A (sh) Novi derivati aminopropanola, postupak za njihovo pravljenje i farmaceutski preparati koji sadrže iste
JPH10507446A (ja) ビス−２−アミノピリジン類、その製造方法及び寄生虫感染を制御するためのその用途
HUP0003856A2 (hu) 6-Pirrolidin-2-ilpirindin-származékok, eljárás előállításukra és gyógyászati alkalmazásuk
MA31031B1 (fr) NOUVEAUX DÉRIVÉS AMINOPYRROLO[1,2-a]INDOLE ET AMINOPYRIDAZINO[1,6-a]INDOLE, LEUR PROCÉDÉ DE PRÉPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
ATE219675T1 (de) Pharmazeutische zubereitung zur behandlung sogenannter rastloser beine
Ibnat A review on the novel Heterocyclic Antileishmanial drugs for the treatment of Leishmaniasis
BR0209035A (pt) Antagonistas de receptor crf
EP1222169A1 (en) Novel trisubstituted pyridine compounds
KR950032131A (ko) 헤테로고리 화합물, 이것을 포함한 약제학적 조성물 및 이것들의 제조방법
JPH02160790A (ja) ジアンヒドロヘキシトールのアシル誘導体

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A , 9A E 10 ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.